Use of injectable CAB/RPV LA as replacement ART in virally suppressed adults with HIV
This guideline was developed by the New York State Department of Health (NYSDOH) AIDS Institute (AI). Its purpose is to provide healthcare practitioners with information on the use of injectable long-acting cabotegravir/rilpivirine (CAB/RPV LA) as replacement therapy for adults (≥18 years old) with...
| Main Author: | |
|---|---|
| Corporate Authors: | , |
| Format: | eBook |
| Language: | English |
| Published: |
[Albany, N.Y.]
New York State Department of Health AIDS Institute
2021, July 2021
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | This guideline was developed by the New York State Department of Health (NYSDOH) AIDS Institute (AI). Its purpose is to provide healthcare practitioners with information on the use of injectable long-acting cabotegravir/rilpivirine (CAB/RPV LA) as replacement therapy for adults (≥18 years old) with HIV who are virally suppressed (HIV RNA level <50 copies/mL) [FDA 2021]. The goal is to ensure that clinicians understand:1. The risks and benefits of switching to injectable antiretroviral therapy (ART)2. How to engage patients in shared decision-making regarding treatment3. How to develop protocols within their institution or medical practice to deliver injectable ART based on currently available evidence from published clinical trial data |
|---|---|
| Physical Description: | 1 PDF file (18 pages) illustrations |